Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ISG15 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ISG15 Wild-Type & Conjugation-Deficient Mutant (LRLRAA) Recombinant Proteins High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 & E. coli expressed. |
View ISG15 Products |
| Gene Delivery | ISG15 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View ISG15 Products |
| Benchmark Ab | Anti-ISG15 Benchmark Antibodies (Biosimilars) Recombinant positive control for neutralization and ELISA assays. |
View ISG15 Products |
| Validator | ISG15 siRNA Set For knockdown verification in target validation studies. |
View ISG15 Products |
| Related Target A | USP18 The major deISGylating enzyme and negative regulator of Type I IFN signaling; critical counter-screening partner. |
View USP18 Products |
| Related Target B | UBA7 (UBE1L) The E1 activating enzyme initiating the intracellular ISGylation cascade. |
View UBA7 Products |
| Related Target C | ITGAL (CD11a/LFA-1) The cell surface receptor mediating extracellular ISG15-induced cytokine release. |
View ITGAL Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Distinguishing extracellular cytokine effects from intracellular ISGylation | Conjugation-deficient mutant (LRLRAA C-terminal mutation) available alongside Wild-Type ISG15 |
| Assay reproducibility across species | Human and Mouse ortholog proteins strictly sequence-verified and purity-tested |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live ISG15 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ISG15 therapeutics is intensifying, with major players shifting focus from traditional intracellular targets to targeting extracellular ISG15 as an immunomodulatory cytokine. As first-generation therapies reach the clinic, the next wave of R&D is targeting the dual nature of ISG15—acting both as a ubiquitin-like modifier (intracellular ISGylation) and as an alarmin/cytokine in the tumor microenvironment (TME).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Neutralizing mAb | Academic/Biotech Consortia | Solid Tumors, Autoimmune Diseases | LFA-1 binding blockade assay (Need high-purity WT ISG15 and LFA-1 proteins) |
| Small Molecule Inhibitors | Preclinical Startups | Viral Infections, Cancer Immunotherapy | In vitro ISGylation assay (Need active recombinant UBA7, UBE2L6, and ISG15) |
| Gene Therapy / siRNA | RNAi Developers | Ovarian & Breast Cancers | Target knockdown validation (Need sequence-validated ISG15 siRNA) |